Mumbai investor Niraj Shah buys 6.44% stake in zero-revenue Bacil Pharma
Shah picks up 925,000 shares over three days as other holders reduce. The nano-cap reported zero operating revenue for FY26 but may be eyeing a fundraise.
— 8 earlier stories on Bacil Pharma Ltd. →What's new
- Niraj Shah bought 925,000 shares (6.44% stake) via open market from June 22-24.
- Bacil Pharma has zero operating revenue and a market cap of just ₹57 crore.
- The purchase follows recent stake sales by two other non-promoter shareholders.
Why this matters
A new substantial holder entering a nano-cap with no revenue is a bet on a turnaround or a future fundraise. The board is set to discuss fundraising on June 26, and Shah's entry just days before may signal confidence in that plan.
What we're watching
- Outcome of the board meeting on June 26 regarding fundraising.
- Whether Shah increases his stake further or other holders follow suit.
- Any change in Bacil's revenue trajectory in coming quarters.
The full read
The timing is hard to ignore. Niraj Rajnikant Shah bought 925,000 shares, a 6.44% stake, over three trading days just before Bacil Pharma's board meets on June 26 to discuss fundraising. The nano-cap with a ₹57 crore market cap reported zero operating revenue for FY26. Two other non-promoter shareholders had reduced their stakes earlier in June. Shah's entry into a zero-revenue company is a bet that the board's fundraise can change the trajectory. It is a bet without revenue cover, only a board decision.
Questions answered
- Who is Niraj Rajnikant Shah?
- He is a Mumbai-based investor who has bought 925,000 shares of Bacil Pharma, becoming a 6.44% stakeholder. No other background is disclosed in the filing.
- Why is this stake purchase notable?
- Bacil Pharma is a nano-cap with zero operating revenue in the latest fiscal year. Such a large stake acquisition by a new investor suggests a bullish view on the company's plans, especially with a board meeting on fundraising scheduled for June 26.
- What does 'zero operating revenue' mean for Bacil Pharma?
- The company reported no revenue from operations for the year ended March 2026. Its only income appears to be from other sources, as net profit was ₹1 crore in the March 2026 quarter.
- How does this purchase compare with recent selling by other shareholders?
- Earlier in June, Manubhai Shah sold a 2.75% stake and Nikita Patel sold a 7.10% stake. Niraj Shah's purchase reverses part of that selling and adds a new name to the shareholder list.
Bacil Pharma Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on BACPHAR →- 29 Jun 2026 · 11:07 AM IST Mumbai investor Niraj Shah buys 6.44% stake in zero-revenue Bacil Pharma
- 11d ago Bacil Pharma loses another large holder as Shah sells 2.75% stake
- 12d ago Bacil Pharma loses another big holder — Patel cuts stake by 7.10%
- 13d ago Bacil Pharma board to mull fundraising options on June 26
- 18d ago Bacil Pharma proposes R&D arm, but numbers are missing